Brand | Generic | Basic Info |
Cosentxy | secukinumab | MOA: IL-17 inhibitor
Indications: Plaque Psoriasis, Psoriatic Arthritis
Administration(general): SubQ, Monthly
Unique ADES: IBD exacerbation/new onset |
Enbrel | etanercept | MOA: TNF inhibitor
Indications: Plaque Psoriasis, Psoriatic Arthritis,RA,JIA
Administration(general): SubQ, weekly
Unique ADEs: Cardiac,CNS
Biosimilar: Erelzi |
Humira | adalimumab | MOA: TNF inhibitor
Indications: Plaque Psoriasis, Psoriatic Arthritis,RA, IBD,JIA,+
Administration(general):SubQ, Q2 Week
Unique ADEs: Cardiac,CNS
Biosimilars:Amjevita and Cyltezo |
Otezla | aprimilast | MOA: PDE-4 inhibitor
Indications: Plaque Psoriasis, Psoriatic Arthritis
Administration(general): PO, BID
Unique ADEs: GI (severe), Psych
Titration pack available |
Remicade | infliximab | MOA: TNF inhibitor
Indications: Plaque Psoriasis, Psoriatic Arthritis,RA,IBD,JIA,+
Administration(general): IV, Q2 month
Unique ADEs: Cardiovascular, CNS, infusion reaction (premedicate)
Biosimilars: Renflexis, Inflectra |
Siliq | brodalumab | MOA: IL-17 inhibitor
Indications: Plaque Psoriasis
Administration(general): SubQ, Q2 week
Unique ADEs: Suicidal Ideation (BBW and REMS), IBD exacerbation/new onset |
Stelara | ustekinumab | MOA: IL-12,23 inhibitor
Indications: Plaque Psoriasis, Psoriatic Arthritis,IBD
Administration(general):SubQ, Q3 months
Unique ADEs: Neurotoxicity (RPLS) |
Taltz | ixekizumab | MOA: IL-17 inhibitor
Indications: Plaque Psoriasis
Administration(general): SubQ, Monthly
Unique ADES: IBD exacerbation/new onset |
Tremfya | guselkumab | MOA: IL-23 inhibitor
Indications: Plaque Psoriasis
Administration(general): SubQ, Q2 months |
Cimzia | certolizumab | MOA: TNF inhibitor
Indications:, Psoriatic Arthritis,RA, IBD,+
Administration(general): SubQ, monthly
Unique ADEs: Anemias, CNS, Cardiac |
Simponi | golimumab | MOA: TNF inhibitor
Indications:Psoriatic Arthritis,RA, IBD,+
Administration(general):SubQ,monthly
Unique ADEs: Anemias, CNS, Cardiac |
Actemra | tocilzumab | MOA: IL-6 inhibitor
Indications: RA
Administration(general): SUbQ, Weekly |
Kineret | anakinra | MOA: IL-1 inhibitor
Indications: RA, +
Administration(general): SubQ,daily
Unique ADEs: Neuotrophilia(SEVERE) monitor monthly x 3 months, then q3months |
Orencia | abatacept | MOA: T-cell costim-blocker
Indications: Psoriatic Arthritis,RA
Administration(general):SubQ, weekly
Unique ADEs: Worse outcomes in COPD patients |
Xeljanx | tofactinib | MOA: JAK STAT inhibitor
Indications: RA,IBD
Administration(general):PO, BID (QD for XR)
Unique ADES: Bradycard/arrythmia, anemias(dose adjust),liver injury(monitor),lipids (monitor)
Renal and Hepatic Dosing- 5mg QD |
Entyvio | vedolizumab | MOA: CAM-1 inhibitor
Indications: IBD
Administration(general):IV, Q2 months
Unique ADES: Liver injury, PML |
Inflammatory Conditions Generalizations:
Methotrexate OKAY
do NOT double up biologics
TNF blockers 1st line biologics | Vaccinate before initiation: NO LIVE VACCINES during therapy.
Avoid in Preg/BF
Many also used for Ankylosing spondylitis | Warnings for: Infection, Malignancy
TB testing, HepB/C, testing
SubQ: Refrigerate, don't freeze or shake. Thigh,back of arm, abdomen(rotate) |